The Cooper Companies Reports Q3 Earnings: $98.3 Million, Revenue of $1.06 Billion
PorAinvest
miércoles, 27 de agosto de 2025, 4:30 pm ET1 min de lectura
COO--
The company's COO segment delivered strong growth, with revenues expected to increase 6-7% in fiscal 2025. The CVI segment, which includes contact lenses, is anticipated to grow 6.5% organically. Meanwhile, the CSI segment, focusing on gynecological surgical devices, is projected to grow 2.7% organically. The company expects Q4 revenue to range between $1.05 billion and $1.07 billion, with full-year earnings projected between $4.08 and $4.12 per share.
Despite the revenue miss, the company's earnings beat was driven by strong demand for contact lenses and surgical devices. The CVI segment, which includes popular brands like MyDay and Biofinity, is expected to continue its growth trajectory. The CSI segment, which includes devices like ALLY Uterine manipulator and Fetal Pillow, also showed strength.
The company's earnings beat was predicted by Zacks Investment Research, which noted the positive Earnings ESP and Zacks Rank #2 for COO [1]. Other medical stocks, such as Cardinal Health (CAH) and McKesson (MCK), also have favorable earnings surprise potential.
In conclusion, while The Cooper Companies missed revenue expectations, its earnings beat was driven by strong demand for its products. Investors should closely monitor the company's Q4 earnings and full-year guidance to gauge its performance.
References:
[1] https://www.nasdaq.com/articles/cooper-companies-likely-beat-q3-earnings-estimate-lens-demand
[2] https://www.sharewise.com/us/news_articles/The_Cooper_Companies_COO_Q3_Earnings_Preview_What_You_Should_Know_Beyond_the_Headline_Estimates_Zacks_20250822_1515
The Cooper Companies reported fiscal Q3 earnings of $98.3 million, beating expectations with a per-share net income of 49 cents. Adjusted earnings were $1.10 per share, exceeding the average estimate of $1.07 per share. Revenue was $1.06 billion, falling short of expectations. The company expects Q4 revenue of $1.05 billion to $1.07 billion and full-year earnings of $4.08 to $4.12 per share.
The Cooper Companies, Inc. (COO) reported its fiscal Q3 2025 earnings, beating expectations but falling short on revenue. The company reported a per-share net income of 49 cents, exceeding the average estimate of 42 cents [1]. Adjusted earnings were $1.10 per share, surpassing the consensus estimate of $1.07 per share. However, revenue totaled $1.06 billion, falling short of the expected $1.07 billion.The company's COO segment delivered strong growth, with revenues expected to increase 6-7% in fiscal 2025. The CVI segment, which includes contact lenses, is anticipated to grow 6.5% organically. Meanwhile, the CSI segment, focusing on gynecological surgical devices, is projected to grow 2.7% organically. The company expects Q4 revenue to range between $1.05 billion and $1.07 billion, with full-year earnings projected between $4.08 and $4.12 per share.
Despite the revenue miss, the company's earnings beat was driven by strong demand for contact lenses and surgical devices. The CVI segment, which includes popular brands like MyDay and Biofinity, is expected to continue its growth trajectory. The CSI segment, which includes devices like ALLY Uterine manipulator and Fetal Pillow, also showed strength.
The company's earnings beat was predicted by Zacks Investment Research, which noted the positive Earnings ESP and Zacks Rank #2 for COO [1]. Other medical stocks, such as Cardinal Health (CAH) and McKesson (MCK), also have favorable earnings surprise potential.
In conclusion, while The Cooper Companies missed revenue expectations, its earnings beat was driven by strong demand for its products. Investors should closely monitor the company's Q4 earnings and full-year guidance to gauge its performance.
References:
[1] https://www.nasdaq.com/articles/cooper-companies-likely-beat-q3-earnings-estimate-lens-demand
[2] https://www.sharewise.com/us/news_articles/The_Cooper_Companies_COO_Q3_Earnings_Preview_What_You_Should_Know_Beyond_the_Headline_Estimates_Zacks_20250822_1515

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios